ERBB2 and breast cancer: A randomized phase III TANIA trial demonstrated that continuing bevacizumab with weekly paclitaxel as second-line chemotherapy for locally recurrent/metastatic HER-2 negative BC after progression on first-line bevacizumab-containing therapy significantly improved PFS compared with chemotherapy alone (HR 0.75, 95%; CI 0.61-0.93), although this did not translate into a significant OS advantage [36].